Arzneimittelforschung 2008; 58(7): 348-352
DOI: 10.1055/s-0031-1296518
Immunomodulators · Immunostimulants · Immunosuppressants
Editio Cantor Verlag Aulendorf (Germany)

High-performance Liquid Chromatography Method for the Determination of Mycophenolic Acid in Human Plasma and Application to a Pharmacokinetic Study of Mycophenolic Acid Dispersible Tablet

Wei Zhang
1  Center for Instrumental Analysis, China Pharmaceutical University (Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education), Nanjing, People’s Republic China
,
Bing-ren Xiang
1  Center for Instrumental Analysis, China Pharmaceutical University (Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education), Nanjing, People’s Republic China
,
Jing Zhang
2  Jiangsu Provincial People’s Hospital, Nanjing, People’s Republic China
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)

Abstract

A sensitive and selective high-performance liquid chromatographic-ultraviolet (HPLC-UV) method for the determination of mycophenolic acid (MPA, CAS 24280-93-1) in human plasma has been developed. Sample treatment was based on protein precipitation with a trichloroacetic acid-water (10:90, w/v) solution. The analytical determination was carried out by HPLC with ultraviolet detection at 254 nm. Chromatographic separation was achieved on a C18 column by isocratic elution with acetonitrile-water (pH 4.4) (50:50, v/v) at a flow rate of 1.0 mL/min. The method was linear in the concentration range of 0.2–50.0 μg/mL. The lower limit of quantification (LLOQ) was 0.2 μg/mL. The intra-day and inter-day relative standard deviations across three validation runs over the entire concentration range were less than 7.05%. The accuracy determined at three concentrations (0.4, 5.0 and 20.0 μg/mL for MPA) was within ± 10.0%. The method was successfully applied to the evaluation of the pharmacokinetic profile of MPA dispersible tablet in 20 healthy volunteers. The results showed that AUC, Cmax and T1/2 for the test and reference formulations were not significantly different (P > 0.05). The relative bioavailability was 96.42 ± 15.5%.